{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:32:36Z","timestamp":1793151156959,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK122028"],"award-info":[{"award-number":["R01 DK122028"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL169530"],"award-info":[{"award-number":["R01 HL169530"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhepr.2026.101886","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:50:42Z","timestamp":1777942242000},"page":"101886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel pharmacological inhibitor of MAP4K4 activity attenuates metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-498X","authenticated-orcid":false,"given":"Felix","family":"Ampadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-4405","authenticated-orcid":false,"given":"Nikhil","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswararao","family":"Eeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-9463","authenticated-orcid":false,"given":"Woncheol","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan M.","family":"Abu shukair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8577-2060","authenticated-orcid":false,"given":"Anza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5516-8877","authenticated-orcid":false,"given":"Yuriana","family":"Aguilar-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyu","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-9009","authenticated-orcid":false,"given":"Vibhudutta","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-5144","authenticated-orcid":false,"given":"Aditya D.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101886_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101886_bib2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","article-title":"Molecular mechanisms in MASLD\/MASH-related HCC","volume":"82","author":"Wang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101886_bib3","doi-asserted-by":"crossref","first-page":"G433","DOI":"10.1152\/ajpgi.00337.2024","article-title":"Cinnabarinic acid protects against metabolic dysfunction-associated steatohepatitis by activating aryl hydrocarbon receptor-dependent AMPK signaling","volume":"328","author":"Patil","year":"2025","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhepr.2026.101886_bib4","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101886_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101886_bib6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101886_bib7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101886_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/jpet.124.002065","article-title":"Role of mitogen-activated protein kinase kinase kinase kinase 4 signaling in liver and metabolic diseases","volume":"390","author":"Ampadu","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhepr.2026.101886_bib9","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1038\/s41388-021-02007-w","article-title":"MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3","volume":"40","author":"Singh","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2026.101886_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100238","article-title":"Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage","volume":"63","author":"Anand","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhepr.2026.101886_bib11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acs.oprd.1c00130","article-title":"Catalyst-free and scalable process for synthesis of novel MAP4K4 inhibitor DMX-5804 and its glyco-conjugates","volume":"25","author":"Eeda","year":"2021","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.jhepr.2026.101886_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1073\/pnas.91.2.674","article-title":"Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha","volume":"91","author":"Wu","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101886_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.122.001301","article-title":"Cinnabarinic acid provides hepatoprotection against non-alcoholic fatty liver disease","volume":"383","author":"Patil","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhepr.2026.101886_bib14","article-title":"Biologically intact therapeutic exosomes from human hepatic progenitor cells for liver diseases","volume":"15","author":"Kim","year":"2026","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.jhepr.2026.101886_bib15","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.3390\/molecules27165111","article-title":"Mulberry leaf extract improves metabolic syndrome by alleviating lipid accumulation in vitro and in vivo","volume":"27","author":"He","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jhepr.2026.101886_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2337\/db12-0325","article-title":"VASP increases hepatic fatty acid oxidation by activating AMPK in mice","volume":"62","author":"Tateya","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2026.101886_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.114.222265","article-title":"Aryl hydrocarbon receptor-dependent stanniocalcin 2 induction by cinnabarinic acid provides cytoprotection against endoplasmic reticulum and oxidative stress","volume":"353","author":"Joshi","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhepr.2026.101886_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/molpharm.121.000376","article-title":"Decoding cinnabarinic acid specific stanniocalcin 2 induction by aryl hydrocarbon receptor","volume":"101","author":"Patil","year":"2022","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101886_bib19","article-title":"A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML","volume":"5","author":"Guo","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2026.101886_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nmeth1048","article-title":"A semisynthetic epitope for kinase substrates","volume":"4","author":"Allen","year":"2007","journal-title":"Nat Methods"},{"key":"10.1016\/j.jhepr.2026.101886_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53003","article-title":"STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jhepr.2026.101886_bib22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G\u2217Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul","year":"2009","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.jhepr.2026.101886_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/acsmedchemlett.5b00215","article-title":"Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment","volume":"6","author":"Ammirati","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jhepr.2026.101886_bib24","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1039\/c3sc22205e","article-title":"Glucose conjugation for the specific targeting and treatment of cancer","volume":"4","author":"Calvaresi","year":"2013","journal-title":"Chem Sci"},{"key":"10.1016\/j.jhepr.2026.101886_bib25","first-page":"364","article-title":"Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes","volume":"40","author":"Ndefo","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.jhepr.2026.101886_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114519","article-title":"A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction","volume":"188","author":"Nam","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101886_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074436","article-title":"Direct regulation of cytochrome c oxidase by calcium ions","volume":"8","author":"Vygodina","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101886_bib28","doi-asserted-by":"crossref","first-page":"8243","DOI":"10.1074\/jbc.M115.637785","article-title":"Mitochondrial turnover: a phenotype distinguishing brown adipocytes from interscapular brown adipose tissue and white adipose tissue","volume":"290","author":"Gospodarska","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhepr.2026.101886_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tem.2016.04.006","article-title":"Map4k4 signaling nodes in metabolic and cardiovascular diseases","volume":"27","author":"Virbasius","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2026.101886_bib30","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/MCB.00150-15","article-title":"Inducible deletion of protein kinase Map4k4 in obese mice improves insulin sensitivity in liver and adipose tissues","volume":"35","author":"Danai","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2026.101886_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100669","article-title":"GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action","volume":"65","author":"Cansby","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhepr.2026.101886_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dsx.2021.02.037","article-title":"Role of CaMKII in the regulation of fatty acids and lipid metabolism","volume":"15","author":"Joseph","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jhepr.2026.101886_bib33","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2147\/DMSO.S210764","article-title":"Salidroside-mitigated inflammatory injury of hepatocytes with non-alcoholic fatty liver disease via inhibition TRPM2 ion channel activation","volume":"12","author":"Feng","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jhepr.2026.101886_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijmm.2022.5169","article-title":"Role of Ca(2+) channels in non-alcoholic fatty liver disease and their implications for therapeutic strategies","volume":"50","author":"Chen","year":"2022","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jhepr.2026.101886_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.996667","article-title":"CaM\/CaMKII mediates activation and proliferation of hepatic stellate cells regulated by ASIC1a","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101886_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12079-022-00680-4","article-title":"The functions of Ca(2+)\/calmodulin-dependent protein kinase II (CaMKII) in diabetes progression","volume":"17","author":"Benchoula","year":"2023","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.jhepr.2026.101886_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cmet.2013.10.011","article-title":"Activation of calcium\/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling","volume":"18","author":"Ozcan","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2026.101886_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2012.03.002","article-title":"Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity","volume":"15","author":"Ozcan","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2026.101886_bib39","article-title":"D-Mannose regulates hepatocyte lipid metabolism via PI3K\/Akt\/mTOR signaling pathway and ameliorates hepatic steatosis in alcoholic liver disease","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101886_bib40","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.930638","article-title":"The serum metabolomics study of liver failure and artificial liver therapy intervention","volume":"27","author":"Huang","year":"2021","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jhepr.2026.101886_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13287-022-02906-z","article-title":"Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt\/beta-catenin signaling pathway in mice","volume":"13","author":"Liu","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jhepr.2026.101886_bib42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3389\/fphar.2019.01353","article-title":"Comparative network pharmacology analysis of classical TCM prescriptions for chronic liver disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101886_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12964-020-00572-3","article-title":"Ethanol-activated CaMKII signaling induces neuronal apoptosis through Drp1-mediated excessive mitochondrial fission and JNK1-dependent NLRP3 inflammasome activation","volume":"18","author":"Lim","year":"2020","journal-title":"Cell Commun Signal"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:13Z","timestamp":1793147953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589555926001576"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101886","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel pharmacological inhibitor of MAP4K4 activity attenuates metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101886"}}